Ectopic growth hormone-releasing hormone secretion by a bronchial carcinoid tumor: Clinical experience following tumor resection and long-Acting octreotide therapy

Peter W. Butler, Craig S. Cochran, Maria J. Merino, Dao Nguyen, David S. Schrump, Phillip Gorden

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Acromegaly resulting from the ectopic secretion of growth hormone-releasing hormone (GHRH) is rare. We present a case of acromegaly secondary to proven GHRHsecretion by a bronchial carcinoid tumor in a type 1 diabetic subject and document the clinical course pre- and postresection of the tumor and of subsequent octreotide therapy. A 54-year-old Caucasian man was referred for evaluation of acromegalic symptoms and significantly increased insulin requirements. He had a history of left lung surgery 20 years prior for hemoptysis. Initial laboratory results indicated acromegaly. Fasting serum growth hormone (GH): 26.1 ng/mL (0-5 ng/mL), insulin-like growth factor 1 (IGF-1): 635 ng/mL (87-283 ng/mL), GH at 60 min post-ingestion of 75 grams of oral glucose during a glucose tolerance test: 8.3 ng/mL (normal<1 ng/mL). Pituitarymagnetic resonance imaging (MRI) revealed diffuse pituitary enlargement without adenoma. A 4.4 cm left hilar mass was noted on chest computed tomography (CT) scan. Further evaluation for a suspected GHRH-secreting neuroendocrine tumor was pursued. Plasma GHRH level was elevated: 198 pg/mL (<50 pg/mL). Octreoscan showed radiolabelled-octreotide uptake in the left lung mass and pituitary gland. Surgical resection of the lung mass was performed. Immunohistochemical study of the tumor tissue indicated a neuroendocrine tumor secreting GHRH. Postoperatively, serum GHRH, GH and IGF-1 levels fell precipitously. At 10 months, IGF-1 levels were mildly elevated and 7 months of 10 mg longacting octreotide therapy (Sandostatin® LAR®) was trialed. At 20 months, off octreotide, serum IGF-1 levels had normalized, acromegalic features were receding, and the patient's daily insulin requirements had decreased by 57%.

Original languageEnglish
Pages (from-to)260-265
Number of pages6
JournalPituitary
Volume15
Issue number2
DOIs
StatePublished - Jun 1 2012
Externally publishedYes

Fingerprint

Ectopic Hormones
Growth Hormone-Releasing Hormone
Octreotide
Carcinoid Tumor
Somatomedins
Acromegaly
Growth Hormone
Neuroendocrine Tumors
Neoplasms
Lung
Serum
Insulin
Therapeutics
Symptom Assessment
Hemoptysis
Pituitary Gland
Glucose Tolerance Test
Adenoma
Fasting
Thorax

Keywords

  • Acromegaly
  • Carcinoid
  • Ectopic acromegaly
  • Growth hormone-releasing hormone
  • Neuroendocrine tumor
  • Octreotide
  • Somatostatin analogue

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Ectopic growth hormone-releasing hormone secretion by a bronchial carcinoid tumor : Clinical experience following tumor resection and long-Acting octreotide therapy. / Butler, Peter W.; Cochran, Craig S.; Merino, Maria J.; Nguyen, Dao; Schrump, David S.; Gorden, Phillip.

In: Pituitary, Vol. 15, No. 2, 01.06.2012, p. 260-265.

Research output: Contribution to journalArticle

Butler, Peter W. ; Cochran, Craig S. ; Merino, Maria J. ; Nguyen, Dao ; Schrump, David S. ; Gorden, Phillip. / Ectopic growth hormone-releasing hormone secretion by a bronchial carcinoid tumor : Clinical experience following tumor resection and long-Acting octreotide therapy. In: Pituitary. 2012 ; Vol. 15, No. 2. pp. 260-265.
@article{e599506649cc409da138e9db843c1b37,
title = "Ectopic growth hormone-releasing hormone secretion by a bronchial carcinoid tumor: Clinical experience following tumor resection and long-Acting octreotide therapy",
abstract = "Acromegaly resulting from the ectopic secretion of growth hormone-releasing hormone (GHRH) is rare. We present a case of acromegaly secondary to proven GHRHsecretion by a bronchial carcinoid tumor in a type 1 diabetic subject and document the clinical course pre- and postresection of the tumor and of subsequent octreotide therapy. A 54-year-old Caucasian man was referred for evaluation of acromegalic symptoms and significantly increased insulin requirements. He had a history of left lung surgery 20 years prior for hemoptysis. Initial laboratory results indicated acromegaly. Fasting serum growth hormone (GH): 26.1 ng/mL (0-5 ng/mL), insulin-like growth factor 1 (IGF-1): 635 ng/mL (87-283 ng/mL), GH at 60 min post-ingestion of 75 grams of oral glucose during a glucose tolerance test: 8.3 ng/mL (normal<1 ng/mL). Pituitarymagnetic resonance imaging (MRI) revealed diffuse pituitary enlargement without adenoma. A 4.4 cm left hilar mass was noted on chest computed tomography (CT) scan. Further evaluation for a suspected GHRH-secreting neuroendocrine tumor was pursued. Plasma GHRH level was elevated: 198 pg/mL (<50 pg/mL). Octreoscan showed radiolabelled-octreotide uptake in the left lung mass and pituitary gland. Surgical resection of the lung mass was performed. Immunohistochemical study of the tumor tissue indicated a neuroendocrine tumor secreting GHRH. Postoperatively, serum GHRH, GH and IGF-1 levels fell precipitously. At 10 months, IGF-1 levels were mildly elevated and 7 months of 10 mg longacting octreotide therapy (Sandostatin{\circledR} LAR{\circledR}) was trialed. At 20 months, off octreotide, serum IGF-1 levels had normalized, acromegalic features were receding, and the patient's daily insulin requirements had decreased by 57{\%}.",
keywords = "Acromegaly, Carcinoid, Ectopic acromegaly, Growth hormone-releasing hormone, Neuroendocrine tumor, Octreotide, Somatostatin analogue",
author = "Butler, {Peter W.} and Cochran, {Craig S.} and Merino, {Maria J.} and Dao Nguyen and Schrump, {David S.} and Phillip Gorden",
year = "2012",
month = "6",
day = "1",
doi = "10.1007/s11102-010-0226-7",
language = "English",
volume = "15",
pages = "260--265",
journal = "Pituitary",
issn = "1386-341X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Ectopic growth hormone-releasing hormone secretion by a bronchial carcinoid tumor

T2 - Clinical experience following tumor resection and long-Acting octreotide therapy

AU - Butler, Peter W.

AU - Cochran, Craig S.

AU - Merino, Maria J.

AU - Nguyen, Dao

AU - Schrump, David S.

AU - Gorden, Phillip

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Acromegaly resulting from the ectopic secretion of growth hormone-releasing hormone (GHRH) is rare. We present a case of acromegaly secondary to proven GHRHsecretion by a bronchial carcinoid tumor in a type 1 diabetic subject and document the clinical course pre- and postresection of the tumor and of subsequent octreotide therapy. A 54-year-old Caucasian man was referred for evaluation of acromegalic symptoms and significantly increased insulin requirements. He had a history of left lung surgery 20 years prior for hemoptysis. Initial laboratory results indicated acromegaly. Fasting serum growth hormone (GH): 26.1 ng/mL (0-5 ng/mL), insulin-like growth factor 1 (IGF-1): 635 ng/mL (87-283 ng/mL), GH at 60 min post-ingestion of 75 grams of oral glucose during a glucose tolerance test: 8.3 ng/mL (normal<1 ng/mL). Pituitarymagnetic resonance imaging (MRI) revealed diffuse pituitary enlargement without adenoma. A 4.4 cm left hilar mass was noted on chest computed tomography (CT) scan. Further evaluation for a suspected GHRH-secreting neuroendocrine tumor was pursued. Plasma GHRH level was elevated: 198 pg/mL (<50 pg/mL). Octreoscan showed radiolabelled-octreotide uptake in the left lung mass and pituitary gland. Surgical resection of the lung mass was performed. Immunohistochemical study of the tumor tissue indicated a neuroendocrine tumor secreting GHRH. Postoperatively, serum GHRH, GH and IGF-1 levels fell precipitously. At 10 months, IGF-1 levels were mildly elevated and 7 months of 10 mg longacting octreotide therapy (Sandostatin® LAR®) was trialed. At 20 months, off octreotide, serum IGF-1 levels had normalized, acromegalic features were receding, and the patient's daily insulin requirements had decreased by 57%.

AB - Acromegaly resulting from the ectopic secretion of growth hormone-releasing hormone (GHRH) is rare. We present a case of acromegaly secondary to proven GHRHsecretion by a bronchial carcinoid tumor in a type 1 diabetic subject and document the clinical course pre- and postresection of the tumor and of subsequent octreotide therapy. A 54-year-old Caucasian man was referred for evaluation of acromegalic symptoms and significantly increased insulin requirements. He had a history of left lung surgery 20 years prior for hemoptysis. Initial laboratory results indicated acromegaly. Fasting serum growth hormone (GH): 26.1 ng/mL (0-5 ng/mL), insulin-like growth factor 1 (IGF-1): 635 ng/mL (87-283 ng/mL), GH at 60 min post-ingestion of 75 grams of oral glucose during a glucose tolerance test: 8.3 ng/mL (normal<1 ng/mL). Pituitarymagnetic resonance imaging (MRI) revealed diffuse pituitary enlargement without adenoma. A 4.4 cm left hilar mass was noted on chest computed tomography (CT) scan. Further evaluation for a suspected GHRH-secreting neuroendocrine tumor was pursued. Plasma GHRH level was elevated: 198 pg/mL (<50 pg/mL). Octreoscan showed radiolabelled-octreotide uptake in the left lung mass and pituitary gland. Surgical resection of the lung mass was performed. Immunohistochemical study of the tumor tissue indicated a neuroendocrine tumor secreting GHRH. Postoperatively, serum GHRH, GH and IGF-1 levels fell precipitously. At 10 months, IGF-1 levels were mildly elevated and 7 months of 10 mg longacting octreotide therapy (Sandostatin® LAR®) was trialed. At 20 months, off octreotide, serum IGF-1 levels had normalized, acromegalic features were receding, and the patient's daily insulin requirements had decreased by 57%.

KW - Acromegaly

KW - Carcinoid

KW - Ectopic acromegaly

KW - Growth hormone-releasing hormone

KW - Neuroendocrine tumor

KW - Octreotide

KW - Somatostatin analogue

UR - http://www.scopus.com/inward/record.url?scp=84861455946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861455946&partnerID=8YFLogxK

U2 - 10.1007/s11102-010-0226-7

DO - 10.1007/s11102-010-0226-7

M3 - Article

C2 - 20379782

AN - SCOPUS:84861455946

VL - 15

SP - 260

EP - 265

JO - Pituitary

JF - Pituitary

SN - 1386-341X

IS - 2

ER -